Brief: Lumos Diagnostics Signs Exclusive U.S. Distribution Agreement With Phase Scientific For Febridx
16/07/2025 02:36
July 16 (Reuters) - Lumos Diagnostics Holdings Ltd LDX.AX: SIGNS PIVOTAL, EXCLUSIVE U.S. DISTRIBUTION AGREEMENT WITH PHASE SCIENTIFIC FOR FEBRIDX SIX-YEAR EXCLUSIVE AGREEMENT VALUED AT UP TO US$317 MILLION DEAL FOR US$2.0 MILLION PAYABLE IMMEDIATELY Further company coverage: LDX.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lumos Diagnostics Holdings
See all newsBrief: Lumos Diagnostics Posts FY26 Revenue Of $13.2 Million
Australia's Lumos Diagnostics soars on bagging purchase order for diagnostic test
Brief: Lumos Diagnostics Receives $767,800 Febridx Order From Phase Scientific
Brief: Lumos Diagnostics Signs Exclusive Distribution Agreement For Febridx In Romania
Brief: Lumos Diagnostics Posts FY26 Revenue Rises 6% To $13.2 Million